We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
OVIDREL choriogonadotropin alfa 250 mcg / 0.5mL solution for injection pre-filled syringe (USA)
Section 19A approved medicine
OVIDREL choriogonadotropin alfa 250 mcg / 0.5mL solution for injection pre-filled syringe (USA)
Section 19A approval holder
Merck Healthcare Pty Ltd ABN 72 006 900 830
Phone
1800 633 463
Approved until
Status
Current
Medicines in short supply/unavailable
OVIDREL choriogonadotropin alfa (rch) 250 microgram/0.5mL solution for injection pre-filled pen - ARTG 170446
Indication(s)
OVIDREL is indicated in the treatment of:
- Women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): OVIDREL is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.
- Anovulatory or oligo-ovulatory women: OVIDREL is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.
Images
